Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402618 | 0.86 | TLR8 (0.37) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL6403120 | 0.85 | ALDH1A1 (0.40) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL6401579 | 0.80 | TLR8 (0.40) | TSHRTLR8MCHR1CDK1CCNB1 | |
| SCHEMBL6403131 | 0.80 | TLR8 (0.40) | TSHRTLR8MCHR1CDK1CCNB1 | |
| SCHEMBL6397725 | 0.80 | TLR8 (0.40) | TSHRTLR8MCHR1CDK1CCNB1 | |
| SCHEMBL8689288 | 0.78 | MEN1 (0.38) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL8692203 | 0.73 | MAPT (0.37) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL2990823 | 0.72 | CDK1 (0.46) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL7637855 | 0.72 | MEN1 (0.36) | MAPTLMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL2457239 | 0.71 | ALDH1A1 (0.49) | MAPTLMNAMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5438058-A | More soluble and less side effects (hypertension) than Minoxidil; treating alopecia, pelade and desquamative dermititis | L'OREAL (FR) | 1995-08-01 | — | — | US | claimed |
| EP-0459890-B1 | Composition for use in preventing loss of hair and for inducing and stimulating its growth, containing derivatives of 2-alkyl-4-amino(or -2,4-dialkyl)-pyrimidin-3-oxide and the new derivatives of 2-alkyl-4-amino-pyrimidin-3-oxide | OREAL (FR) | 1994-01-05 | — | — | EP | claimed |
| US-20050049232-A1 | Composition | LINDAU PAR (SE) | 2005-03-03 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| EP-1463483-A1 | NEW COMPOSITION | Ponsus Pharma AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003055454-A1 | NEW COMPOSITION | PONSUS PHARMA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
| US-5438058-A | More soluble and less side effects (hypertension) than Minoxidil; treating alopecia, pelade and desquamative dermititis | L'OREAL (FR) | 1995-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049232-A1 | Composition | CUTA, LIPG, LIPA | MAPT 3490/4885LMNA 212/4885MEN1 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.